Skip to main content

Organon & Co Value Stock - Dividend - Research Selection

Organon & company

ISIN: US68622V1061 , WKN: A3CPKP

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio. It also offers cardiovascular products, consisting of several cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for various treatments to control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. In addition, the company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products primarily to drug wholesalers and retailers, hospitals, and government agencies, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was incorporated in 2020 and is based in Jersey City, New Jersey.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Organon's Supplemental Biologics License Application Gets FDA Approval For TOFIDENCE To Treat Chimeric Antigen Receptor T Cell-Induced Severe Or Life-Threatening Cytokine Release Syndrome

2026-06-10
Organon (NYSE:OGN) today announced the US Food and Drug Administration (FDA) approval of the supplemental Biologics License Application (sBLA) for TOFIDENCE® (tocilizumab-bavi) injection, for intravenous use, a

Organon to Present New Research on Access and Value at ISPOR 2026

2026-05-15
New findings will highlight contraception affordability, biosimilar adoption, and access-focused analyses across the women’s health and general medicines portfolio...

Organon (OGN) Price Target Increased by 25.58% to 11.02

2026-05-14

Are OGN, TBRG, CYCN Obtaining Fair Deals for their Shareholders?

2026-05-04
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers.Shareholders...

An April To Remember For Stocks

2026-05-01
The S&P 500 (SPY) jumped more than 10% in April for its best month since November 2020.

Deal Dispatch: Sirius XM Mulls Purchase Of iHeartMedia, Uber Buys FlyTaxi, Wren Kitchens Bankruptcy

2026-05-01
Major M&A deals this week include: Eli Lilly buys Profluent for $2.2 billion, Lazard buys Campbell Lutyens, FreshRealm bankruptcy.

Organon & Co. Reports Earnings Results for the First Quarter Ended March 31, 2026

2026-04-30
Organon & Co. reported earnings results for the first quarter ended March 31, 2026. For the first quarter, the company reported sales was USD 1,460 million compared to USD 1,513 million a year ago.Net...

Organon Q1 Adj. EPS $0.71 Misses $0.83 Estimate, Sales $1.460B Miss $1.484B Estimate

2026-04-30
Organon (NYSE:OGN) reported quarterly earnings of $0.71 per share which missed the analyst consensus estimate of $0.83 by 14.46 percent. This is a 30.39 percent decrease over earnings of $1.02 per share from the same

Organon: Q1 Earnings Snapshot

2026-04-30
JERSEY CITY, N.J. — JERSEY CITY, N.J. — Organon & Co. on Thursday reported first-quarter profit of $146 million. The Jersey City, New Jersey-based company said it had net income of 55 cents...

Organon Reports Results for the First Quarter Ended March 31, 2026

2026-04-30
First quarter 2026 revenue of $1.460 billion, down 4% as-reported and down 9% excluding the impact of foreign currency.First quarter 2026 diluted earnings per share of $0.55 and non-GAAP Adjusted...